Vaishali Pharma Ltd
Incorporated in 1989, Vaishali Pharma Ltd
does marketing of pharmaceutical products including active pharmaceutical ingredients[1]
- Market Cap ₹ 104 Cr.
- Current Price ₹ 7.99
- High / Low ₹ 12.8 / 4.75
- Stock P/E 23.3
- Book Value ₹ 5.30
- Dividend Yield 0.00 %
- ROCE %
- ROE 6.02 %
- Face Value ₹ 2.00
Pros
Cons
- Promoter holding has decreased over last quarter: -1.07%
- Promoter holding is low: 30.5%
- Earnings include an other income of Rs.3.57 Cr.
- Company has high debtors of 170 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | TTM | |
|---|---|---|
| 109 | 108 | |
| 105 | 104 | |
| Operating Profit | 4 | 4 |
| OPM % | 3.8% | 3.9% |
| 4 | 4 | |
| Interest | 2 | 2 |
| Depreciation | 1 | 1 |
| Profit before tax | 5 | 5 |
| Tax % | 25% | |
| 4 | 4 | |
| EPS in Rs | 0.32 | 0.34 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | -14% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Equity Capital | 26 |
| Reserves | 43 |
| 19 | |
| 35 | |
| Total Liabilities | 123 |
| 2 | |
| CWIP | 0 |
| Investments | 6 |
| 116 | |
| Total Assets | 123 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Net Cash Flow | |
| Free Cash Flow | |
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | 170 |
| Inventory Days | 13 |
| Days Payable | 81 |
| Cash Conversion Cycle | 102 |
| Working Capital Days | 212 |
| ROCE % |
Insights
In beta| Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Countries Exported To count |
|
||||||
| Export Revenue (FOB) Rs. Crores |
|||||||
| Formulation Brands Registered count |
|||||||
| Product Registrations Approved count |
|||||||
| Products in Portfolio count |
|||||||
| Customers count |
|||||||
| Product Registrations Applied count |
|||||||
| Distributors (Export) count |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Copy of Newspaper Publication
- Board approved Q1 FY2026-27 unaudited results on 14 August 2026 and published newspaper advertisement.
-
Resignation of Director/KMP/SMP
- Vaishali Pharma Limited has informed about Resignation of Director/KMP/SMP
-
Resignation of Director/KMP/SMP
- Vaishali Pharma Limited has informed about Resignation of Director/KMP/SMP
-
Resignation of Director/KMP/SMP
- Vaishali Pharma Limited has informed about Resignation of Director/KMP/SMP
-
Resignation
- Mr. Bhaveshkumar Popatlal Upadhyay resigned as Non-Executive Independent Director effective 14 August 2026.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2020TranscriptAI SummaryPPT
-
May 2020TranscriptAI SummaryPPT
Business Overview:[1]
VPL is certified by ISO 9001:2008 and provides 1500+ products and 250+ Brands including APIs, Formulations, Surgical, Herbals, Veterinary, Nutraceutical, Oncology, and other healthcare products in 35+ locations